DrugBank

JULY 18, 2024

Vaccines have consistently demonstrated their efficacy in protecting people from infectious diseases. This led to the eradication of smallpox and polio – two debilitating diseases that historically caused global epidemics. Adjuvants are substances added to vaccines to enhance the immune response.

Vaccine 79

Vaccine Immune Response Clinical Trials Disease 79

The Pharma Data

MAY 16, 2021

Adjuvanted recombinant COVID-19 vaccine candidate triggered strong neutralizing antibody responses in all adult age groups. High immune response after a single dose in patients with prior infection shows strong booster potential. For further information please visit www.gsk.com/about-us. For media and investors only.

Immune Response 52

Immune Response Vaccine Trials Treatment 52

The Pharma Data

JULY 15, 2021

Antibody and T-cell immune responses strong and stable at eight months after immunization Demonstrated neutralizing antibody activity against the Delta variant (B.1.617.2) In addition, the T-cell responses are especially strong and stable over time, which is also potentially important for activity against these variants.”.

Immune Response 52

Immune Response Vaccine Clinical Trials FDA 52

PLOS: DNA Science

MAY 16, 2024

These factors are converging to enable both identification of novel infectious diseases as well as microbial resistance, before these threats can impact public health, write a team from the European Society for Clinical Microbiology and Infectious Diseases in Frontiers in Science. COVID clearly caught us off guard.

Virus 98

Virus DNA RNA Laboratories 98

The Pharma Data

SEPTEMBER 3, 2020

Johnson & Johnson Announces that Janssen’s COVID-19 Investigational Vaccine Candidate Prevents Severe Clinical Disease in Pre-clinical Studies. Johnson & Johnson Announces that Janssen’s COVID-19 Investigational Vaccine Candidate Prevents Severe Clinical Disease in Pre-clinical Studies. Source link.

Vaccine 52

Vaccine Disease Immune Response Pharmaceutical Companies 52

The Pharma Data

OCTOBER 14, 2021

Biogen today announced results of a new analysis of immune response to the COVID-19 vaccine among people with multiple sclerosis (MS). These results demonstrate that MS DMTs impact antibody responses to COVID-19 vaccination in different ways and understanding these differences is crucial,” said Jeffrey Cohen, M.D.,

Vaccine 52

Vaccine Therapies Disease Immune Response 52

DrugBank

MAY 15, 2024

Today, we're able to identify and target specific molecules involved in disease processes—a method that's much more like using a sniper rifle than throwing darts blindfolded. Among these targets are proteins, receptors, and enzymes that are fundamental to disease mechanisms.

Small Molecule 81

Small Molecule Molecular Biology Drugs Disease 81

The Pharma Data

JANUARY 31, 2021

Nasdaq: VIRI), a biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, announced today that it is entering a collaboration with Dr. Michael Camilleri of the Mayo Clinic to explore the role of antiviral therapy in managing Irritable Bowel Syndrome (IBS).

Immune Response 52

Immune Response Research Therapies Disease 52

The Pharma Data

MARCH 31, 2022

The trial aims to understand if different vaccine regimens – prototype and variant vaccines alone and in combinations – can broaden immune responses in adults who already have received a primary vaccination series and a first booster shot. Fauci, M.D. Nadine Rouphael, M.D.,

Clinical Trials 52

Clinical Trials Trials Immune Response Vaccine 52

Drug Target Review

NOVEMBER 17, 2023

NK cells are among the front line of protection from infected and abnormal cells as part of the ‘innate immune response’. They recognise ‘cell stress molecules’ on the surface of infected, old, injured and cancerous cells without the need for complex pre-stimulation signals of the adaptive immune system (eg, T cells).

Therapies 118

Therapies Cell Biology Clinical Trials Trials 118

The Pharma Data

DECEMBER 31, 2020

31, 2020 — Blood vessel damage and inflammation in the brains of deceased COVID-19 patients suggest the damage is not caused by the virus, but the body’s immune response to it. The spots were surrounded by T cells — signs of an immune response. Further Support and Information on COVID-19. THURSDAY, Dec.

Immune Response 52

Immune Response Virus Doctors Research 52

Drug Target Review

JANUARY 15, 2024

The Class I HLA system presents fragments of intracellular antigens to CD8 T cells and allows the immune system to monitor intracellular events, thus providing an essential component of immunity against cancer. CD8+ T cells are a type of lymphocyte that specialises in scanning information presented by HLA Class I.

Engineering 110

Engineering DNA Virus Immune Response 110

Drug Target Review

NOVEMBER 17, 2023

NK cells are among the front line of protection from infected and abnormal cells as part of the ‘innate immune response’. They recognise ‘cell stress molecules’ on the surface of infected, old, injured and cancerous cells without the need for complex pre-stimulation signals of the adaptive immune system (eg, T cells).

Therapies 103

Therapies Clinical Trials Immune Response Trials 103

The Pharma Data

DECEMBER 16, 2020

Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced an Advance Purchase Agreement with the government of New Zealand for the purchase of 10.7 For more information, visit www.novava x.com and connect with us on Twi t ter and Linke d In. GAITHERSBURG, Md.,

Vaccine 52

Vaccine Government Immune Response Clinical Trials 52

The Pharma Data

OCTOBER 9, 2021

years of exposure 3 Design of a new open-label study assessing immune response to SARS-CoV-2 mRNA vaccines in MS-patients treated with Kesimpta 4 , and new findings from open-label study assessing immune response to SARS-CoV-2 mRNA vaccines in secondary progressive MS (SPMS) patients treated with Mayzent will be presented 5.

Immune Response 52

Immune Response Vaccine Treatment Therapies 52

The Pharma Data

DECEMBER 3, 2020

Strong Th1 cell-mediated immune responses were also observed for the vaccine candidates with either adjuvant. We are encouraged by the high level of neutralizing antibodies in combination with the strong Th1 response which we believe could play an important role in controlling infection. About Trimer-Tag © Technology.

Vaccine 52

Vaccine Immune Response Virus RNA 52

Codon

SEPTEMBER 29, 2024

The earliest ones relied on simple linear regression and attempted to correlate genetic variations with observable traits or disease risks — such as drug metabolization rates or cancer susceptibility. Over the decade, entire categories of diseases disappeared. 2024 Statistical models of organisms have existed for decades.

Engineering 132

Engineering Virus DNA Therapies 132

The Pharma Data

AUGUST 24, 2020

Those infected develop an immune response as their bodies fight off the virus which helps to protect them against it returning. The strongest immune response has been found in the most seriously ill patients. But it is still not clear how strong this protection or immunity is – or how long it lasts.

Virus 52

Virus Immune Response Vaccine Hospitals 52

The Pharma Data

DECEMBER 8, 2020

Overall, the vaccine protected against symptomatic disease in 70% of cases, according to a team led by researchers from Oxford University in England. ” Previous clinical trials of the vaccine had found that the vaccine triggers antibody and T-cell immune responses, and is safe in people aged 18 and older. TUESDAY, Dec.

Vaccine 52

Vaccine Trials Immune Response RNA 52

The Pharma Data

MARCH 8, 2022

Also, the incidence of severe disease progression was observed to be significantly reduced. Like other members of this genus, SARS-CoV-2 is equipped with several molecular tools that allow it to evade recognition by the immune system. The mouse model we used recapitulates key aspects of the human COVID-19 disease,” added Prof.

Clinical Pharmacology 52

Clinical Pharmacology Immune Response RNA Virus 52

The Pharma Data

JUNE 30, 2021

Yasmin Parr’s study of FeLV shows that the outcome of FeLV infection is influenced by the host immune response, with progressively infected cats, so cats whose conditions are worsening, having weaker immune responses. “In For more information, please visit www.abcdcatsvets.org. References.

Immune Response 52

Immune Response Virus Disease Doctors 52

The Pharma Data

JULY 8, 2021

In addition, the data showed that the durability of the immune response lasted through at least eight months, the length of time evaluated to date. In addition, we observe a persistent and particularly robust, durable cellular immune response,” said Mathai Mammen, M.D., 2) variants during the study period.

Vaccine 52

Vaccine Immune Response Pharmaceutical Companies Disease 52

The Pharma Data

SEPTEMBER 25, 2020

The data demonstrate that a single dose of JNJ-78436735 induced a strong neutralizing antibody response in nearly all participants aged 18 years and older and was generally well-tolerated. Immune responses were similar across the age groups studied, including older adults. Immune Response Data. Source link.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

OCTOBER 6, 2021

years of exposure 3 Design of a new open-label study assessing immune response to SARS-CoV-2 mRNA vaccines in MS-patients treated with Kesimpta 4 , and new findings from open-label study assessing immune response to SARS-CoV-2 mRNA vaccines in secondary progressive MS (SPMS) patients treated with Mayzent will be presented 5.

Immune Response 52

Immune Response Vaccine Treatment Therapies 52

The Pharma Data

NOVEMBER 22, 2020

The partnership will harness both FJB and IONTAS’ proprietary antibody libraries and technology platforms to investigate novel therapeutic targets for autoimmune and inflammatory diseases. The TALON effector modules are based on immunomodulatory molecules that act as regulatory control points within the immune system. Source link.

Immune Response 52

Immune Response Engineering Clinical Research Disease 52

The Pharma Data

JANUARY 22, 2021

The EUA covers adults and children over age 12 who have mild or moderate COVID-19 and are at high risk for severe disease. The Weinreich article also reports that the “antibody cocktail reduced viral load, with a greater effect in patients whose immune response had not yet been initiated or who had a high viral load at baseline.

Immune Response 52

Immune Response Clinical Trials Hospitals Trials 52

The Pharma Data

JANUARY 12, 2021

Ben-Moshe told BioSpace that BND-22 differs from traditional immunotherapy in that it can elicit a more total immune response. . “It It is a new immune checkpoint that is expressed on three different immune cells: Macrophages, [Natural Killer] NK cells, and T cells. [It]

Immune Response 52

Immune Response Clinical Trials Licensing Licensing 52

The Pharma Data

JUNE 26, 2021

We believe that mRNA technology could have several advantages for a seasonal flu application including the potential ability to demonstrate robust immune responses based on preclinical data to date, enable antigen specificity within a short timeframe from seasonal virus strain selection, and deploy agile manufacturing capacity.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

MAY 31, 2022

Pneumococcal disease includes pneumonia, meningitis, bloodstream infections, and milder diseases such as sinusitis and otitis media and remains a significant unmet medical need despite the availability of current pneumococcal vaccines. pneumoniae invasive disease and pneumonia in adults 50 years and above. Pneumococcal disease.

Vaccine 52

Vaccine Immune Response Clinical Trials Disease 52

The Pharma Data

MARCH 11, 2021

Clinical trial to assess safety, immune response and reactogenicity, after preclinical data showed high neutralizing antibody levels. the vaccines global business unit of Sanofi, to develop mRNA vaccines for up to five infectious disease pathogens. Expected to enroll 415 participants; interim results expected in Q3 2021.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

FEBRUARY 22, 2021

New Phase 2 study assesses potential for refined antigen formulation to achieve optimal immune response, including in older adults. Results of the Phase 2 trial will inform the Phase 3 protocol. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions. About the Phase 2 study.

Vaccine 52

Vaccine Immune Response Trials Clinical Trials 52

Drug Target Review

OCTOBER 17, 2024

While its involvement in the do-not-eat-me signal from cancer has inspired therapeutic development of this pathway for oncology, the function of the innate immune checkpoint we identified in 2009 1 extends to both innate and adaptive immune responses. CD24 and Siglec-10 Selectively Repress Tissue Damage-Induced Immune Responses.

Immune Response 52

Immune Response Clinical Trials Trials Therapies 52

Drug Target Review

OCTOBER 10, 2024

What are the risks of over-reliance on healthy donor material in early-stage research, and how can decision-makers ensure a balanced integration of diseased material to avoid potential gaps when transitioning to clinical trials? Diseased cells are likely to be more fragile or less abundant, making it difficult to obtain enough for therapy.

Therapies 52

Therapies Immune Response Clinical Trials Disease 52

The Pharma Data

JULY 6, 2021

In addition, the data showed that the durability of the immune response lasted through at least eight months, the length of time evaluated to date. In addition, we observe a persistent and particularly robust, durable cellular immune response,” said Mathai Mammen, M.D., 2) variants during the study period.

Vaccine 52

Vaccine Immune Response Clinical Trials Disease 52

The Premier Consulting Blog

APRIL 18, 2024

The Cell and Gene Therapy (CGT) field has unprecedented potential to effectively treat and/or cure genetic-based rare and orphan diseases and expand the reach of personalized medicine. This blog will outline three characteristics of a successful nonclinical program to support entry into clinical trials for a cell or gene therapy product.

Therapies 52

Therapies Clinical Trials Small Molecule Immune Response 52

The Pharma Data

JANUARY 9, 2021

Centers for Disease Control and Prevention, if you have a severe allergic reaction after the first shot, you should not get the second shot. But such patients should be warned of the possibility that they will have a lower immune response. Further Support and Information on COVID-19. According to the U.S. Source link.

Vaccine 52

Vaccine Immune Response Doctors Disease 52

The Pharma Data

NOVEMBER 18, 2020

.” Goza notes that although the likelihood of spreading the disease may vary among different-aged children, children can and do spread the virus. To understand any potential unique immune responses and/or safety concerns, children must be included in vaccine trials, Goza writes. . ” Sept. 17 Letter. Source link.

Vaccine 52

Vaccine Trials Immune Response Virus 52